| Neuroligin 1 (NLGN1) | |
|---|---|
| Gene | [NLGN1](/genes/nlgn1) |
| UniProt | Q13404 |
| PDB | 3DMU, 3BIW |
| Mol. Weight | 98 kDa (full-length) |
| Localization | Postsynaptic membrane, excitatory synapses |
| Family | Neuroligin family, cell adhesion molecules |
| Diseases | [Autism](/diseases/autism), [Alzheimer's Disease](/diseases/alzheimers), [Schizophrenia](/diseases/schizophrenia), [ALS](/diseases/als) |
Neuroligin 1 (NLGN1) is a postsynaptic cell adhesion molecule that plays a critical role in synapse formation, maintenance, and plasticity throughout the central nervous system. As a member of the neuroligin family (NLGN1-5 in humans), it mediates trans-synaptic adhesion by binding to presynaptic neurexin proteins, forming functional synaptic connections essential for proper neural circuitry development and function.
NLGN1 is predominantly localized at excitatory glutamatergic synapses, where it serves as a key organizer of postsynaptic machinery. The receptor recruits and clusters essential postsynaptic proteins, including NMDA receptors, AMPA receptors, and postsynaptic density scaffolds, thereby establishing proper synaptic transmission. Beyond its foundational role in synaptogenesis, NLGN1 has emerged as a critical player in neurodegenerative diseases, particularly Alzheimer's disease, where synaptic loss represents the strongest correlate of cognitive decline.
Mutations in NLGN1 and other synaptic adhesion molecules have been implicated in neurodevelopmental disorders including autism spectrum disorder (ASD), intellectual disability, and schizophrenia. The strategic position of NLGN1 at the synapse makes it both a vulnerability in neurodegeneration and a promising therapeutic target for restoring synaptic function.
The NLGN1 gene (Gene ID: 22871) is located on chromosome 3q26.31 in humans, spanning approximately 35 kb of genomic DNA. The gene consists of 19 exons that encode the complete protein sequence. Multiple alternative splicing events produce tissue-specific and activity-dependent isoforms:
| Exon | Function |
|---|---|
| Exon 1-2 | 5' UTR and signal peptide |
| Exon 3-14 | Extracellular domain (acetylcholinesterase-like) |
| Exon 15 | Transmembrane domain |
| Exon 16-19 | Cytoplasmic tail, including PDZ-binding motif |
The NLGN1 promoter contains several regulatory elements:
NLGN1 is a type I transmembrane protein with distinctive structural domains:
| Domain | Amino Acids | Function |
|---|---|---|
| Signal peptide | 1-18 | Targets protein to secretory pathway |
| Propeptide | 19-26 | Cleaved during maturation |
| Acetylcholinesterase-like domain | 27-650 | Neurexin binding, enzymatic homology |
| O-linked glycosylation sites | Multiple | Cell surface targeting, interactions |
| Transmembrane helix | 651-673 | Membrane anchoring |
| Cytoplasmic tail | 674-843 | PDZ-binding, signaling interactions |
The extracellular acetylcholinesterase-like domain shares structural homology with cholinesterases but lacks enzymatic activity. This domain contains the neurexin-binding interface with a conserved splice site (site B) that determines binding specificity. Dimerization occurs through the extracellular domain, forming functional homodimers that enhance synaptic adhesion strength.
The neurexin-binding site on NLGN1 is highly conserved:
NLGN1 functions as a homodimer at the postsynaptic membrane:
This dimeric structure is essential for proper synaptic adhesion and signaling.
NLGN1 is essential for formation of excitatory synapses: [1]
The neurexin-NLGN1 interaction is bidirectional:
NLGN1 is crucial for proper synaptic transmission: [2]
NLGN1 plays a central role in synaptic plasticity: [3]
| Region | Expression Level | Primary Function |
|---|---|---|
| Hippocampus (CA1, CA3) | Very high | LTP/LTD, memory circuits |
| Cortex (Layer II/III) | High | Corticocortical integration |
| Striatum | Moderate | Motor learning, reward |
| Cerebellum | Moderate | Motor coordination |
| Thalamus | Low-Moderate | Sensory relay |
| Brainstem | Variable | Autonomic regulation |
NLGN1 participates in multiple signaling cascades:
NLGN1 dysfunction is a critical feature of AD pathogenesis: [4]
Tau pathology affects NLGN1 function: [5]
Targeting NLGN1 offers therapeutic opportunities: [6]
NLGN1 mutations cause synaptic dysfunction in ASD: [7]
NLGN1 is implicated in schizophrenia pathophysiology: [8]
NLGN1 plays a role in ALS: [9]
NLGN1 is affected by neuroinflammation: [10]
| Approach | Mechanism | Development Status | Application |
|---|---|---|---|
| Neurexin modulators | Enhance NLGN1-NRXN binding | Research | AD, ASD |
| AAV-NLGN1 | Gene therapy for expression | Preclinical | AD |
| Small molecules | Stabilize synaptic adhesion | Research | AD, PD |
| Peptide mimetics | Trans-synaptic adhesion enhancers | Research | Various |
AAV-mediated NLGN1 delivery shows promise: [11]
Dean C, et al. Structure of neuroligin-neurexin complex (2003). 2003. ↩︎
Craig AM, Kang J. Neuroligins and synaptogenesis (2007). 2007. ↩︎
Liu A, et al. Neuroligin1 in LTP and memory (2020). 2020. ↩︎
Naito Y, et al. Neuroligin in Alzheimer's disease (2017). 2017. ↩︎
Yang J, et al. Neuroligin-1 and tau pathology (2021). 2021. ↩︎
Petersen J, et al. NLGN1 and cognitive function (2022). 2022. ↩︎
Heng J, et al. Neuroligin mutations in neurodevelopmental disorders (2023). 2023. ↩︎
Uemura T, et al. neuroligin-1 and neuropsychiatric disease (2019). 2019. ↩︎
Chen J, et al. Neuroligin-1 and ALS (2022). 2022. ↩︎
Gangwar RS, et al. Neuroligin-1 and neuroinflammation (2023). 2023. ↩︎
Witte M, et al. AAV-NLGN1 gene therapy (2022). 2022. ↩︎